MRI Pituitary Gland – Generic Standard Protocol

MRIninja Knowledge Base | Master / General Page Version 1.0 — April 2026 | Evidence review through April 2026 Audience: Radiologists · Neuroradiologists · Endocrinologists · MRI Technologists · Advanced Students

1. Executive Summary

MRI of the pituitary gland and sellar region is the gold-standard imaging modality for evaluation of the hypothalamic-pituitary axis. Its unique ability to directly visualise the glandular parenchyma, the pituitary stalk, the optic chiasm, and the cavernous sinuses — at the resolution required to detect lesions as small as 2–3 mm — makes it irreplaceable in the endocrine and neuroradiological workup of both hyperfunctioning and hypofunctioning pituitary disease [1, 2].

The pituitary gland imposes specific and demanding imaging requirements that distinguish this protocol from all others in the MRIninja knowledge base. The normal adult pituitary gland measures only 8–12 mm in height, 8–14 mm in transverse diameter, and 10–15 mm in anteroposterior depth. Meaningful microadenomas — lesions with major endocrine significance (Cushing’s disease, acromegaly, prolactinoma) — may be as small as 2–3 mm. This scale demands slice thicknesses of 2–3 mm without gap, the smallest practical field of view compatible with full sellar and parasellar coverage (~16–20 cm), and high-resolution matrices. No other brain or head and neck protocol operates at this spatial resolution requirement.

The second defining feature is the pharmacokinetic relationship between the pituitary gland and gadolinium-based contrast agents. The adenohypophysis lacks a blood-brain barrier and enhances rapidly and intensely after intravenous GBCA. Pituitary microadenomas — which also lack a BBB but have a slightly different and delayed blood supply — enhance later and less avidly than normal parenchyma. This creates a transient contrast differential between normal gland (rapidly enhancing) and adenoma (relatively hypointense by comparison) that is maximally exploitable by dynamic contrast-enhanced (DCE) imaging acquired within the first 30–90 seconds after injection. This enhancement window is the diagnostic basis for the DCE sequence, which has no equivalent in any other MRI protocol in this series.

Compared with CT, MRI provides decisively superior soft-tissue characterisation of the pituitary gland and is the first-line investigation for all pituitary indications [1]. CT is complementary for assessment of osseous sellar wall destruction, sphenoid sinus anatomy before trans-sphenoidal surgery, and in patients with MRI contraindications.

1.1 Core Strengths

• Microadenoma detection: High-resolution thin-slice sequences combined with dynamic contrast enhancement detect lesions ≥ 2–3 mm that define treatment decisions in Cushing’s disease, acromegaly, and prolactinoma.
• Macroadenoma characterisation: Full three-plane assessment of mass size, extension (suprasellar, cavernous sinus invasion, Knosp grading), optic chiasm contact and displacement, internal architecture, and signal characteristics.
• Parasellar anatomy: Cavernous sinuses, internal carotid arteries, optic nerves and chiasm, diaphragma sellae, infundibulum, and hypothalamus — all directly assessable in a single examination.
• Pituitary stalk assessment: The normal stalk tapers cranially and measures ≤ 3 mm at the hypothalamic junction. Thickening, displacement, or signal change narrows a critical differential.
• Normal gland signal characterisation: The neurohypophysis (posterior pituitary) is normally T1-bright (a key diagnostic landmark); its absence requires explanation. The adenohypophysis enhances uniformly post-contrast.
• No ionising radiation: Essential for serial follow-up and in reproductive-age women.

1.2 Intrinsic Limitations of the Generic Protocol

The generic standard pituitary protocol is designed as a broad-sensitivity survey for the most common indications. Its compromises must be understood:

Microadenoma detection sensitivity: The standard non-dynamic post-contrast T1 protocol has sensitivity for pituitary microadenomas of approximately 50–70%, significantly inferior to the DCE protocol [5]. The standard protocol will miss a proportion of small functional microadenomas, particularly those in Cushing’s disease where ACTH-secreting adenomas may be smaller than 5 mm and invisible without dedicated dynamic sequences.

Scale of coverage: The pituitary protocol focuses on the sellar and parasellar region within a small FOV. It does not provide a brain survey. When the clinical question extends to the entire hypothalamic-pituitary axis, cavernous sinuses bilaterally, or skull base, a brain protocol or dedicated expanded coverage must be added.

No functional or perfusion information: Standard morphological MRI cannot directly assess glandular function, perfusion reserve, or lesion blood flow characteristics beyond the basic enhancement pattern.

Post-operative assessment complexity: Post-operative pituitary MRI is technically and interpretively demanding. Surgical haemostasis material, fat packing, and tissue reorganisation produce complex signal patterns that overlap with residual/recurrent adenoma. A dedicated post-operative protocol with early (< 72 hours) or delayed (> 3 months) imaging is required.

When a dedicated child protocol is required: Cushing’s disease (dedicated DCE with petrosal sinus sampling correlation), acromegaly (pre-operative planning), suspected MRI-occult functional adenoma (DCE-MRI essential), post-operative surveillance, Rathke’s cleft cyst complex characterisation, craniopharygioma, suspected cavernous sinus invasion (Knosp grading), suspected pituitary apoplexy with acute onset, paediatric pituitary assessment, and pituitary MRA for suspected aneurysm.

2. Main Clinical Indications

2.1 Standard Indications

General protocol note: Because intravenous access is typically already in place and patient repositioning between pre- and post-contrast phases is undesirable, inclusion of a dynamic contrast-enhanced (DCE) acquisition adds little practical time burden while significantly improving overall examination completeness. Routine use of DCE is therefore reasonable in most contrast-administered pituitary MRI studies.

Suspected or confirmed hyperprolactinaemia is the most frequent indication for pituitary MRI in clinical practice. MRI characterises prolactin-secreting adenomas (prolactinomas), assesses lesion size (micro vs. macro), and establishes the relationship between the adenoma and optic chiasm. The generic protocol with dynamic or post-contrast T1 is generally sufficient for initial assessment; for very small or MRI-occult prolactinomas suspected by biochemistry, DCE is the preferred approach. The ACR Appropriateness Criteria [1] designate MRI of the sella as “usually appropriate” for hyperfunctioning pituitary adenoma (including hyperprolactinaemia, acromegaly, Cushing’s) as the initial imaging investigation.

Acromegaly (GH-secreting adenoma): GH-secreting adenomas are detectable on standard pituitary MRI in the majority of cases, as they are more frequently macroadenomas than prolactinomas. Microadenomas do occur and may require DCE for detection. Standard protocol is appropriate for initial assessment; pre-surgical planning requires full extension characterisation.

Cushing’s disease (ACTH-secreting adenoma): This is the most diagnostically demanding pituitary indication. ACTH-secreting microadenomas are the smallest functional pituitary adenomas, with up to 40% measuring < 6 mm at surgery [3]. The standard protocol has inadequate sensitivity; DCE-MRI is the recommended technique. This is the primary reason DCE should be considered mandatory — not optional — when Cushing’s disease is the clinical question.

Hypopituitarism / pituitary insufficiency: MRI evaluates the gland for structural causes of hypopituitarism — including pituitary hypoplasia, empty sella, post-surgical or post-radiotherapy changes, infiltrative disease (lymphocytic hypophysitis, sarcoidosis, histiocytosis), and mass effect from non-functioning adenomas. The standard non-contrast protocol with post-contrast T1 is generally sufficient for initial structural assessment [1].

Non-functioning pituitary adenoma (NFPA) / pituitary incidentaloma: NFPAs are the most common pituitary tumours overall. The standard protocol characterises size, extension, cavernous sinus invasion, and optic chiasm relationship. For lesions identified incidentally on brain MRI, the ACR Incidental Findings Committee algorithm [4] guides management decisions based on imaging features. The generic protocol is sufficient for initial characterisation; serial surveillance imaging does not require DCE in confirmed stable lesions.

Craniopharyngioma and other suprasellar masses: The standard protocol with pre- and post-contrast T1 and T2 is appropriate for initial characterisation. Cystic components, solid enhancement, calcification pattern (CT may be complementary), and suprasellar extension are assessed. Detailed surgical planning may require additional sequences.

Diabetes insipidus: The normal posterior pituitary T1-bright spot — the neurohypophysis — is the primary target. Its absence is the most important finding. The standard non-contrast protocol with high-resolution sagittal T1 is the recommended initial study [1].

Pituitary apoplexy: Acute haemorrhage into a pituitary adenoma producing sudden headache, visual loss, and diplopia. An emergency for the patient, if severe. Haemorrhage is best characterised on non-contrast T1 (methemoglobin T1-bright after 24–48 hours) and GRE/SWI for early blood products. CT may be performed first in acute presentations. For sequence-level protocol optimisation, vendor terminology and artefact management, see the dedicated MRIninja page Susceptibility Weighted Imaging (SWI) Sequence.

Post-operative surveillance: MRI is the standard for post-operative assessment of residual or recurrent adenoma and pituitary function. Specific timing requirements apply (see Section 6.3). The generic protocol is modified for post-operative interpretation requirements.

Precocious puberty (paediatric): ACR Appropriateness Criteria [1] designate MRI of the sella as the recommended initial investigation in precocious puberty in children. Assessment of glandular size and morphology, presence of an adenoma, and hypothalamic hamartoma.

2.2 Urgent Red Flags Requiring Expedited or Emergency Imaging

3. Preparation Reference

Universal MRI preparation is centralised in the MRIninja Patient Preparation master page. The following covers only items specific to pituitary MRI.

3.1 Anatomy-Specific Preparation Items

Prior pituitary surgery: Trans-sphenoidal surgery (endoscopic or microscopic) is the most common neurosurgical procedure in pituitary disease. Postoperative changes include fat packing of the resection cavity, haemostatic material (Gelfoam, Surgicel), and titanium micro-instruments occasionally left in situ. These are generally MRI-compatible and do not preclude imaging, but modify the expected post-operative signal appearance. A history of prior trans-cranial surgery (frontal craniotomy for large tumours) must also be documented.

Brain stimulation devices and implants: Cochlear implants, DBS (deep brain stimulation) leads, and aneurysm clips in the brain require individual MR compatibility assessment. Sellar aneurysm clips (rare, placed at surgery for sellar/parasellar aneurysm) require device-specific clearance.

Pacemakers and cardiac devices: If the patient has a conditional pacemaker or ICD, the protocol must be adapted to SAR limits. Contact cardiology for device clearance before scheduling.

Metallic dental work: Metallic dental restorations, crowns, and bridges adjacent to the jaw generate susceptibility artefacts that may propagate into the sphenoid sinus and degrade signal at the sella floor. Removable dental prostheses should be removed. Fixed metalwork cannot be removed; document and anticipate susceptibility artefact at the sphenoid sinus level.

Claustrophobia: The pituitary examination is performed in the head coil — the patient’s head is within the coil and the bore. Claustrophobic patients should be managed per the general preparation protocol. Anxiolytic pre-medication may be appropriate in severe cases.

Gadolinium administration readiness: Pituitary MRI in most clinical indications requires gadolinium. IV access should be established before the patient enters the scanner. The dynamic acquisition requires synchronised injection with scan start — this requires a power injector or clearly timed manual injection and must be communicated to the technologist before the examination begins.

Pregnancy: MRI of the pituitary is generally deferred to the second or third trimester unless clinically urgent. Gadolinium is not recommended during pregnancy without specific clinical justification.

Patient history modifying the protocol: - Cushing’s disease: DCE protocol mandatory - Post-operative follow-up: specific timing required (see Section 6.3) - Suspected apoplexy: add GRE/SWI for haemorrhage - Suspected aneurysm: add MRA sequences - Diabetes insipidus: posterior pituitary T1-bright spot assessment — non-contrast protocol; sagittal T1 is primary - Paediatric patient: modified coverage; paediatric normal values

3.2 Patient Positioning on the MRI System

Patient position: Supine, head-first entry. Standard brain/head coil positioning. The head must be in neutral position — no flexion, extension, or rotation.

Coil selection: A dedicated multichannel head coil (8 to 32 channels) is the standard. Modern phased-array head coils provide high SNR uniformly across the brain including the deep sellar region. A 32-channel head coil provides superior SNR for thin-slice high-resolution pituitary imaging compared to older 8-channel designs. Body coil-only pituitary imaging is not acceptable for diagnostic quality at the required resolution.

Centering: The isocentre should be placed at the level of the external auditory meatus, corresponding to the base of the brain and the sellar region. This positions the pituitary gland and sella turcica within the region of maximum coil element sensitivity.

Head alignment: The midsagittal plane of the head must align with the scanner bore axis. The coronal images provide the primary diagnostic planes; any head rotation produces oblique cuts through the pituitary gland that misrepresent the true glandular dimensions and falsely suggest lateral displacement of the stalk or gland.

Immobilisation: Foam pads within the head coil on both sides of the head reduce lateral micromotion. Adequate padding eliminates the need for straps. The patient should be instructed to keep the eyes closed and avoid swallowing during the dynamic acquisition.

Pre-scan technologist checks: 1. Confirm correct head coil activation on console. 2. Verify neutral head position — no lateral tilt, no rotation. 3. Confirm IV access for gadolinium; confirm power injector or manual injection plan for dynamic sequence. 4. Acquire three-plane localiser and verify sella, optic chiasm, and pituitary stalk are visible and within the planned slice coverage before starting. 5. Note any dental metalwork location for documentation.

4. Standard Protocol Design

The pituitary protocol is fundamentally different from the brain protocol in its architecture: thin-slice (2–3 mm) high-resolution acquisitions in a small FOV (~160–200 mm) focused on the sella, combined with dynamic contrast enhancement for microadenoma detection. Whereas brain MRI uses large FOV sequences for parenchymal coverage, pituitary MRI sacrifices coverage breadth for resolution depth.

4.1 Mandatory Core Sequences

Note on DCE status: In centres performing pituitary MRI to a high standard, DCE (sequence #4) is considered mandatory for all pituitary examinations, not conditional. The ACR Appropriateness Criteria and major endocrine societies recommend DCE for functional adenoma detection [1, 2]. At minimum, it is mandatory when a functional (hormonal) microadenoma is the clinical suspicion.

4.2 Conditional Sequences

4.3 Rationale Summary Per Sequence

Coronal T1 TSE (pre-contrast, thin-slice) — the anatomical baseline and primary microadenoma detection sequence for non-DCE protocols. The coronal plane is the most informative single plane for the pituitary gland: it shows glandular height and symmetry, the infundibulum (stalk), the superior sellar contour (convex or flat), the cavernous sinuses bilaterally, and the relationship between the superior gland margin and the optic chiasm.

The normal adenohypophysis appears isointense to grey matter on T1. The normal neurohypophysis appears T1-hyperintense (“posterior pituitary bright spot”) — a key diagnostic landmark whose absence requires explanation (central diabetes insipidus, ectopic posterior pituitary, pituitary stalk interruption syndrome). The sagittal plane is the most reliable for visualising the posterior bright spot.

Microadenomas classically appear as focal T1 hypointense areas within the otherwise isointense gland on pre-contrast T1 — due to their altered tissue composition and delayed enhancement. However, this finding is present in only approximately 50–60% of microadenomas on non-enhanced T1 alone; sensitivity is substantially improved by DCE [5].

What it detects well: Glandular morphology and height; posterior pituitary bright spot; haemorrhage within an adenoma (T1-bright methemoglobin); gross macroadenoma; Rathke’s cleft cyst (T1-bright proteinaceous content); lipoma of the sellar region.

What it misses: Most microadenomas without dynamic contrast; isoenhancing adenomas; early post-operative changes.

Technologist note: Slice thickness ≤ 3 mm without gap is mandatory. Any gap between slices risks missing a small microadenoma that falls between slices. This is the single most important technical parameter in pituitary imaging.

Coronal T2 TSE (thin-slice) — tissue characterisation and cystic component detection. T2-weighted images provide complementary information to T1: lesions with high water content (cysts, Rathke’s cleft cysts, arachnoid cysts) appear T2-bright; solid adenomas are typically T2-isointense to grey matter; fibrous or desmoplastic lesions (meningiomas) are T2-hypointense.

Important T2 signal relationships for pituitary lesions: - Soft-textured, T2-hyperintense adenoma: typically prolactinoma or growth hormone adenoma (granular cell subtype) — predicts good medical response - T2-hypointense (dark) adenoma: typically fibrous or densely granulated GH adenoma — may predict resistance to somatostatin analogues [2, 6] - Markedly T2-bright content: cystic lesion (Rathke’s cleft cyst, arachnoid cyst, craniopharyngioma cyst) - Heterogeneous T2 signal with T1-bright areas: haemorrhage (apoplexy)

What it detects well: Cystic component characterisation; cavernous sinus anatomy and flow voids; optic chiasm compression; fibrous vs. soft adenoma differentiation; aneurysm (flow void in ICA or parasellar vessel).

Limitation: T2 is less sensitive than post-contrast T1 for adenoma detection; sensitivity approximately 68.7% in one series [7]. Coronal T2 alone is not sufficient for adenoma detection.

Technologist note: Copy exact slice geometry from coronal T1 for direct level-by-level comparison. Any angulation mismatch between T1 and T2 coronal series degrades the comparative value of both sequences.

Sagittal T1 TSE (pre-contrast) — midline anatomy and posterior pituitary assessment. The sagittal plane provides the best single view of: the pituitary stalk from hypothalamus to the gland, the posterior pituitary bright spot, the optic chiasm position relative to the suprasellar region, the anterior and posterior sellar walls, the diaphragma sellae, and the sphenoid sinus anatomy immediately below.

What it detects well: Posterior pituitary bright spot (present or absent); stalk anatomy (straight, deviated, thickened); suprasellar extension of macroadenoma and its relationship to the chiasm (“snowman” configuration); empty sella; cerebrospinal fluid pulsation artefacts in the suprasellar cistern.

Dynamic contrast-enhanced T1 (DCE) — the gold standard for pituitary microadenoma detection. This is the sequence that makes pituitary MRI unique in the entire MRIninja protocol series. The DCE sequence exploits the pharmacokinetic difference between normal adenohypophysis (rapid, intense enhancement within 30 seconds) and pituitary microadenoma (slower, delayed enhancement due to different blood supply).

The pharmacokinetic basis: the adenohypophysis is directly supplied by portal venules from the hypothalamus, which enhances very rapidly. Most pituitary adenomas are supplied by the inferior hypophyseal arteries of the cavernous ICA directly, with no portal supply; they consequently enhance more slowly. During the first 30–90 seconds after injection, the normal gland becomes markedly hyperintense while the adenoma remains relatively hypointense — a transient contrast differential that is the diagnostic basis of the DCE examination. After approximately 2–5 minutes, the adenoma progressively enhances and the differential is lost.

DCE technical requirements: Sequential rapid coronal thin-slice T1 acquisitions of the pituitary, beginning immediately before contrast injection and continuing through at least 60–120 seconds after injection. Each acquisition should ideally take no more than 20–30 seconds per frame to capture the rapid pharmacokinetic changes. Faster temporal resolution improves depiction of the early enhancement curve, particularly the wash-in phase, where contrast differentiation between normal gland and microadenoma is greatest. The standard approach uses 1 pre-contrast acquisition followed by 3–5 post-contrast acquisitions at 20–30 second intervals.

What DCE detects well: Microadenomas as small as 2–3 mm that are invisible on standard post-contrast T1; the correct lateralisation of a microadenoma for surgical planning; persistent versus washout enhancement patterns.

Limitation: DCE requires technical precision (timing, injection protocol, motion control) — any patient motion during the dynamic series produces misregistration that degrades or eliminates the differential signal. DCE is also limited by spatial resolution trade-offs: the short acquisition time per frame forces the use of lower resolution or thicker slices compared to the delayed static post-contrast series.

Coronal and Sagittal T1 post-contrast (static, delayed) — the complementary post-contrast structural assessment acquired after the DCE, at approximately 3–5 minutes after injection. At this time, the normal gland and most adenomas have both enhanced, allowing reliable anatomical assessment of lesion boundaries, cavernous sinus invasion, stalk enhancement, optic chiasm relationship, and overall tumour morphology. The delayed post-contrast T1 has the highest spatial resolution in the entire pituitary protocol and is used for surgical planning and macroadenoma characterisation.

4.4 Sequence Matching and Cross-Sequence Consistency

Coronal series matching: All coronal sequences (T1 pre, T2, DCE, T1 post) must share identical slice geometry — same angulation, same coverage, same number of slices, same slice thickness. Any geometric mismatch between pre- and post-contrast coronal T1 makes comparison of enhancement impossible and may lead to systematic false-negative or false-positive conclusions. On modern scanners, copy the geometry from the pre-contrast T1 coronal to all subsequent coronal sequences.

Pre/post contrast T1 matching: This is the most critical matching requirement in pituitary MRI. The pre-contrast coronal T1 is the reference against which the adenoma’s relative hypoenhancement is assessed. Geometric mismatch between pre- and post-contrast makes this comparison unreliable. Subtraction imaging (post-contrast minus pre-contrast) is not routinely used in pituitary MRI in most centres (unlike in some brain enhancement applications), but is valid and improves microadenoma conspicuity when implemented. The DCE series, by definition, includes a pre-contrast frame that serves as the baseline.

Sagittal series: Sagittal T1 pre- and post-contrast should share identical geometry.

Serial follow-up reproducibility: For serial pituitary adenoma surveillance, identical slice geometry, coil configuration, and field strength must be maintained. When comparing imaging for adenoma growth assessment, any change in protocol parameters may simulate size change. Protocol parameters should be archived with each examination.

4.5 Fat Suppression and Region-Specific Technical Modifiers

Fat suppression is not a component of the standard pituitary protocol. The sellar region contains minimal fat structures; the cavernous sinuses, adenohypophysis, neurohypophysis, and parasellar structures do not require fat suppression for their primary diagnostic assessment. The sphenoid sinus floor contains no relevant fat; the cavernous sinus fat content is not a diagnostic target.

Exceptions where fat suppression is added: - Orbital involvement or optic nerve assessment in parasellar/suprasellar tumours extending to the orbital apex: coronal fat-suppressed T2 improves optic nerve characterisation - Suspected craniopharyngioma with fat content: T1-bright fat in a suprasellar cyst can be confirmed by fat suppression (signal loss on T1 fat-suppressed confirms fat, distinguishing from methemoglobin or proteinaceous content) - Cavernous sinus meningioma evaluation: fat-suppressed T1 post-contrast may improve meningioma enhancement conspicuity against the cavernous sinus fat - Post-operative fat packing: Abdominal fat used to pack the sellar resection cavity is T1-bright. Post-operative fat-suppressed T1 pre- and post-contrast sequences are used to distinguish fat packing from residual/recurrent tumour

STIR in pituitary imaging: Not standard. STIR can detect bone marrow oedema within the sphenoid bone (invasive adenoma, clival involvement, metastasis) and is used in specific oncological indications, but is not part of the standard pituitary protocol. For sequence-level protocol optimisation, vendor terminology and artefact management, see the dedicated MRIninja page STIR Sequence.

Dixon technique: Increasingly used for post-operative pituitary MRI to produce simultaneous fat and water images from a single T1 acquisition, enabling distinction of fat packing from enhancing residual tumour. Not standard in non-operated pituitary protocols.

Spontaneus T1 hyperintensity: When an unexpected focal T1 hyperintensity is identified within or adjacent to the pituitary gland on the standard non-fat-suppressed T1 sequence, a dedicated T1 sequence with fat suppression should be added before concluding the examination. This additional acquisition is essential for characterisation: lipomatous lesions (lipoma, dermoid cyst, craniopharyngioma with fat content) will lose signal on fat-suppressed T1, confirming their fatty composition; proteinaceous content (Rathke's cleft cyst with high protein concentration), subacute haemorrhage (methemoglobin in pituitary apoplexy), and melanin-containing lesions will maintain their T1 hyperintensity despite fat suppression [16, 17]. This simple two-step approach — standard T1 followed by fat-suppressed T1 — resolves the majority of ambiguous sellar T1 hyperintensities without requiring additional contrast or invasive investigation. STIR or Dixon fat suppression are preferred over spectral fat saturation for this purpose, given the B0 inhomogeneity at the sphenoid sinus level that may cause spectral method failure in the inferior sellar slices.

5. Optimisation Strategy

5.1 Artifact Reduction by Source

Carotid artery pulsation artefact is the dominant artefact in pituitary coronal MRI. The internal carotid arteries pass through both cavernous sinuses flanking the pituitary gland laterally on each side. Their systolic pulsation generates periodic phase-encoding ghosts that propagate in the phase direction. With R-L phase encoding, these ghosts propagate medially — directly through the pituitary gland — and may simulate intrasellar lesions, stalk displacement, or asymmetric glandular signal. S-I phase encoding is therefore the correct choice for coronal pituitary sequences: carotid ghosts are displaced cranially and caudally, away from the sellar content.

Reduction strategies: S-I phase encoding (mandatory for coronal); flow compensation (gradient moment nulling) on coronal T1 sequences; cardiac gating (rarely used, impractical for pituitary routine); saturation bands over the carotid arteries in the neck (reduces inflow signal; useful in specific circumstances); anterior and posterior saturation bands for CSF pulsation on sagittal sequences.

Sphenoid sinus susceptibility artefact: The sphenoid sinus — an air-filled cavity immediately below the sellar floor — generates a local B0 inhomogeneity that degrades fat suppression at the sellar floor level (when fat suppression is applied) and produces susceptibility signal loss at the most inferior sellar slices. This is more severe at 3T. Increasing bandwidth reduces the geometric distortion component. This is the primary reason the most inferior slices of a pituitary protocol should be reviewed critically. When fat suppression is required in the sellar region — for example in post-operative protocols to distinguish fat packing from enhancing residual tumour — spectral fat saturation techniques are unreliable at the sphenoid sinus level due to the local B0 perturbation. STIR or Dixon fat suppression should be preferred in this context: STIR provides B0-independent fat nulling, while Dixon achieves robust fat-water separation through multi-echo phase cycling rather than spectral selectivity, both being substantially less susceptible to the field inhomogeneity generated by the adjacent air-filled sphenoid sinus.

Dental metalwork susceptibility: Metallic dental restorations generate field inhomogeneity that can propagate superiorly into the sphenoid sinus region. Severity depends on location and material. Document and note; if severe, may limit assessment of the sellar floor on inferior coronal slices. When dental artefact significantly compromises diagnostic quality at the sellar floor level, metal artefact reduction techniques should be applied: increasing receiver bandwidth reduces geometric distortion in the frequency-encoding direction; view-angle tilting (VAT) compensates for through-plane distortion; and dedicated metal artefact reduction sequences (MARS — SEMAC or WARP on Siemens, O-MAR on Philips) dramatically reduce susceptibility blooming at the cost of longer acquisition time. At 1.5T, artefact extent is substantially less than at 3T, and standard TSE sequences with increased bandwidth are often sufficient; at 3T, dedicated MARS sequences may be necessary when dental hardware is extensive and located close to the midline.

Motion artefact during DCE: Patient motion between individual DCE frames produces misregistration that eliminates the pharmacokinetic differential. The patient must remain absolutely still for the approximately 3–5 minute DCE acquisition. Instruct the patient to swallow before the dynamic sequence begins and to avoid swallowing during acquisition. Any motion-corrupted DCE frame must be identified before interpretation.

5.2 Protocol Efficiency and Throughput

Standard pituitary protocol with DCE: Pre-contrast coronal T1 + T2 + sagittal T1 + DCE (5–7 minutes for the dynamic series) + post-contrast coronal T1 + sagittal T1 = approximately 30–40 minutes total.

When DCE is not possible: In time-limited settings or if DCE equipment is not possible, the standard static pre- and post-contrast T1 protocol retains diagnostic value for macroadenomas and large microadenomas, but sensitivity for small microadenomas is substantially reduced. For Cushing’s disease in particular, a non-DCE protocol is inadequate.

3D T1 sequences (MPRAGE/VIBE): 3D isotropic post-contrast T1 sequences at 1 mm isotropic enable full multiplanar reconstruction and are increasingly used for surgical planning and radiosurgery. They do not replace the dedicated thin-slice pituitary coronal series because the resolution is lower per plane; they are additive, not substitutive.

When 2D TSE is superior to 3D for pituitary: For the critical pre- and post-contrast thin-slice coronal and sagittal series and for the T2 characterisation sequence, 2D TSE provides more reliable T1/T2 contrast and higher in-plane resolution at the required slice thickness than 3D GRE sequences. The DCE sequence uses 2D or 3D GRE depending on the centre’s approach.

5.3 Field Strength Considerations

Dental metalwork susceptibility: Metallic dental restorations generate field inhomogeneity that can propagate superiorly into the sphenoid sinus region. Severity depends on location and material. Document and note; if severe, may limit assessment of the sellar floor on inferior coronal slices. When dental artefact significantly compromises diagnostic quality at the sellar floor level, metal artefact reduction techniques should be applied: increasing receiver bandwidth reduces geometric distortion in the frequency-encoding direction; view-angle tilting (VAT) compensates for through-plane distortion; and dedicated metal artefact reduction sequences (MARS — SEMAC or WARP on Siemens, O-MAR on Philips) dramatically reduce susceptibility blooming at the cost of longer acquisition time. At 1.5T, artefact extent is substantially less than at 3T, and standard TSE sequences with increased bandwidth are often sufficient; at 3T, dedicated MARS sequences may be necessary when dental hardware is extensive and located close to the midline.

Practical considerations: 3T is strongly preferred for suspected Cushing’s disease microadenoma. For macroadenoma assessment and post-operative follow-up, 1.5T is clinically adequate. Some centres report that the increased artefact burden at 3T (particularly vascular pulsation) partially offsets the SNR gain — careful protocol optimisation is required.

6. Contrast Use Principles Specific to Pituitary MRI

6.1 Non-Contrast Protocol — When Sufficient

The non-contrast pituitary MRI protocol (T1 pre-contrast + T2 coronal + T1 sagittal) is appropriate in a limited set of clinical scenarios: - Posterior pituitary assessment (diabetes insipidus): The posterior bright spot on T1 is assessed without contrast; contrast does not add diagnostic value for this specific indication. - Empty sella assessment: Morphological assessment of the partially or completely empty sella. - Known large macroadenoma with prior imaging: When contrast has been recently administered and repeat imaging is for anatomical comparison only. - Pregnancy: Gadolinium is not recommended without specific clinical justification. - Incidentaloma follow-up in select cases: Recent evidence suggests that for confirmed stable microadenomas under surveillance, non-contrast T1 and T2 may be sufficient for size monitoring, as gadolinium does not add information beyond size measurement in stable lesions [10]. This remains an evolving area — see Section 11.

In all other standard pituitary indications, gadolinium administration is required or strongly recommended.

6.2 Gadolinium Indicated — Pituitary-Specific Contexts

Contrast dose: The standard clinical dose is 0.1 mmol/kg body weight using a macrocyclic GBCA. This is the same standard dose used for brain MRI. A half-dose (0.05 mmol/kg) has been used in some dynamic pituitary protocols to reduce the glandular enhancement and prolong the contrast differential window, but this is not universally established and is not recommended as a standard approach without institutional validation. Macrocyclic agents are preferred in all patients who may require serial pituitary examinations over years (adenoma follow-up, Cushing’s disease) to minimise gadolinium retention risk [1].

Injection technique for DCE: The pharmacokinetic basis of the DCE sequence requires a bolus injection, not a slow drip. The standard is power injector delivery at 2–3 mL/s followed by a 20 mL saline flush at the same rate. Manual injection is acceptable only if it can reliably deliver the full dose within 5–10 seconds. Slow manual injection degrading the bolus profile reduces the peak contrast differential between gland and adenoma, reducing DCE sensitivity. This is the most common cause of non-diagnostic DCE acquisitions.

Injection timing relative to DCE scan start: The first post-contrast DCE frame should begin approximately 5–8 seconds after injection start (immediately after the saline flush completes). In practice, the standard workflow is: 1. Start the pre-contrast DCE frame 2. At the end of the pre-contrast frame, trigger the power injector 3. The post-contrast frames follow automatically at the pre-programmed intervals

Different protocols and vendors have different triggering mechanisms; the technologist must understand the precise timing for their scanner and adapt accordingly.

6.3 Post-Contrast Acquisition Timing — DCE and Static Series

Dynamic (DCE) series timing:

The critical diagnostic window for microadenoma-normal gland contrast differential is approximately 30–90 seconds after injection. The standard DCE protocol acquires: - 1 pre-contrast frame (baseline, immediately before injection) - 3–5 post-contrast frames at 20–30 second intervals

Frame 1 post-contrast (approximately 20–40 seconds after injection): normal adenohypophysis is markedly enhanced; microadenoma appears relatively hypointense — maximum contrast differential.

Frame 2 (approximately 40–70 seconds): differential beginning to decrease as adenoma enhancement increases.

Frame 3–5 (approximately 70–150 seconds): adenoma progressively enhances toward gland intensity; differential largely lost.

The maximum diagnostic yield of the DCE series occurs in the first 30–90 seconds after injection. Any delay in acquisition start or missed frames in this window significantly reduces sensitivity.

Static post-contrast series timing:

After the dynamic series, the static high-resolution coronal and sagittal T1 post-contrast sequences are acquired at approximately 2-10 minutes after injection. At this delayed time point: - Both normal gland and adenoma have enhanced - Lesion boundaries are best defined for size measurement - Cavernous sinus invasion is assessed by enhancement pattern - Stalk, optic chiasm, and parasellar structures are assessed in their enhanced state

Injection time documentation: Injection time must be recorded in PACS and the radiology report for all pituitary contrast examinations. For post-operative follow-up, this enables correlation with prior examination timing.

Post-operative pituitary MRI timing considerations:

Post-operative pituitary MRI interpretation is complicated by post-surgical changes that evolve over time: - Within 48–72 hours after surgery: Early post-operative haemostatic material (fat packing, packing agents) and blood products are present. The pituitary remnant may be difficult to identify. Early imaging is reserved for suspected complications (haematoma, inadequate decompression with visual deterioration). - 2–6 weeks post-operatively: Inflammatory and early remodelling changes produce enhancement patterns that overlap with residual adenoma. This is the period of maximum interpretive difficulty. Most neurosurgical centres avoid routine MRI in this window except for specific clinical concerns. - 3 months post-operatively: The standard timing for the first post-operative surveillance MRI. Fat packing has partially remodelled, inflammatory changes have resolved, and residual adenoma can be distinguished from expected post-surgical changes in most cases. - Serial follow-up: Typically at 3 months, then annually for 5 years if stable, depending on adenoma type and clinical status.

7. Reporting Essentials

7.1 Interpretation Framework

Pituitary MRI interpretation requires assessment of four anatomical categories systematically: the pituitary gland itself, the parasellar region (cavernous sinuses, ICA), the suprasellar region (optic chiasm, hypothalamus, infundibulum), and the surrounding structures (sphenoid sinus, cavernous ICA).

The three-axis framework: 1. Normal variant vs. pathology: Many pituitary “findings” are normal variants — glandular asymmetry in reproductive-age women (physiological upper convexity), posterior bright spot variability, small sellar cysts. The interpreting radiologist must distinguish these from pathology. 2. Functional vs. non-functional: The clinical biochemistry determines whether an adenoma is functional. The MRI report provides morphological information that guides which endocrine tests are needed and what treatment is appropriate. For non-functioning adenomas, the critical imaging information is size, cavernous sinus invasion, and optic chiasm contact. 3. Microadenoma vs. macroadenoma: The ≥10 mm threshold separates microadenomas (managed medically in many cases) from macroadenomas (higher risk of visual compromise, hypopituitarism, and need for surgical resection).

7.2 Mandatory Reporting Checklist

Pituitary gland: - [ ] Glandular height (measure on coronal T1 in midline; normal adults: 3–9 mm; pregnancy/puberty: up to 12 mm) - [ ] Superior sellar contour: flat/concave (normal in adults), convex (may be normal in pregnancy/puberty; pathological if > 10 mm height with upward convexity) - [ ] Internal signal: homogeneous or heterogeneous (T1, T2, post-contrast) - [ ] Focal lesion: present or absent; if present — size (3 measurements), signal T1/T2, enhancement pattern (DCE: first frame; delayed: enhancement relative to gland) - [ ] Posterior pituitary bright spot: present (normal) or absent

Pituitary stalk (infundibulum): - [ ] Position: midline or deviated (specify direction); note that contralateral stalk deviation is a classic (but not specific) sign of ipsilateral microadenoma - [ ] Calibre: normal (tapers cranially, ≤3 mm at hypothalamic junction) or thickened - [ ] Enhancement: normal enhancement or abnormal

Cavernous sinuses (bilateral): - [ ] Knosp grading if adenoma present (grades 0–4 based on relationship between adenoma and ICA) - [ ] Signal and enhancement: normal or abnormal - [ ] ICA calibre and flow void: normal or narrowed (Knosp 4 = ICA encasement)

Optic apparatus: - [ ] Optic chiasm: position (pre-fixed, normal, post-fixed); contact with superior adenoma or suprasellar mass; displacement; signal change - [ ] Optic nerves: include in report if suprasellar extension present

Suprasellar region: - [ ] Suprasellar cistern: normal or effaced - [ ] Hypothalamus: normal or involved - [ ] Third ventricle: normal or compressed (hydrocephalus from large suprasellar extension)

Sellar floor and sphenoid sinus: - [ ] Sellar floor: intact or eroded - [ ] Sphenoid sinus: pneumatisation type (affects surgical approach); signal; mucosal thickening; lesion extension

Technical items: - [ ] Contrast agent used; dose; macrocyclic or linear agent - [ ] DCE acquisition: frames acquired; quality assessment (motion artefact absent/present) - [ ] Slice thickness achieved - [ ] Comparison with prior examinations

7.3 Structured Reporting

Indication → Technique (field strength, sequences, slice thickness, contrast agent, dose, DCE timing, injection method) → Comparison → Findings (pituitary gland, stalk, cavernous sinuses, optic chiasm, suprasellar, skull base, incidental) → Impression (concise, answering clinical question) → Limitations → Critical communication.

Critical communication: Unexpected apoplexy, visual pathway compromise with urgent surgical implication, unexpected malignancy, or unexpected alternative diagnosis (giant aneurysm simulating adenoma) requires direct verbal communication with the referring clinician, documented in the report with time and recipient.

7.4 Incidental Findings — Clinical Decision Framework

Usually benign, no action required: Pituitary cyst < 5 mm with no local mass effect and no endocrine symptoms in asymptomatic adult; partial empty sella with normal glandular remnant; small posterior pituitary T1 hyperintensity variation within normal range; sphenoid sinus mucosal thickening.

Requires documentation, biochemical screening, and follow-up: Pituitary incidentaloma of any size should trigger biochemical evaluation per the ACR Incidental Findings Committee guidelines [4] and the Endocrine Society Guideline [3]. For lesions ≥ 6 mm, pituitary hormone evaluation is recommended. Serial imaging follow-up per Endocrine Society/Pituitary Society guidelines [3, 11].

Specifically: pituitary microincidentaloma (< 10 mm): MRI surveillance at 6–12 months, then annually for 3 years, then less frequently if stable [3]. Pituitary macroincidentaloma (≥ 10 mm) with optic chiasm contact or invasion: ophthalmological assessment and neurosurgical consultation.

Urgent/clinically important: Macroadenoma with optic chiasm compression and no prior diagnosis — ophthalmological assessment and endocrinological evaluation required urgently; unexpected pituitary apoplexy; unexpected aneurysm; unexpected aggressive or malignant sellar mass.

8. MRI Technologist Pearls

8.1 Sequence Order Logic

Recommended standard order: 1. Three-plane localiser — verify pituitary visible; check head alignment (no rotation); check IV access 2. Coronal T1 TSE (pre-contrast, thin-slice) — primary anatomical baseline; used as geometry reference for all subsequent sequences 3. Coronal T2 TSE (thin-slice) — copy geometry from coronal T1 4. Sagittal T1 TSE (pre-contrast, thin-slice) 5. DCE sequence — immediately before contrast injection; inject at pre-contrast frame completion; continue automatically 6. Coronal T1 TSE (post-contrast, high-resolution delayed) — at approximately 5–10 min after injection; copy geometry from pre-contrast coronal T1 7. Sagittal T1 TSE (post-contrast) — copy geometry from pre-contrast sagittal T1 8. Optional sequences (axial T1/T2, GRE/SWI, MRA) as indicated

Rationale: Pre-contrast T1 and T2 are acquired first — they are the mandatory baseline. The DCE sequence is time-critical and must be positioned precisely before the contrast injection. Post-contrast static sequences follow the dynamic at 5–10 minutes.

8.2 Positioning Tricks

• Head alignment check before starting: Look at the three-plane localiser. On the coronal localiser, the midline structures (falx, nasal septum, septal cartilage) must be perfectly central. Even 5° of head rotation produces apparent stalk deviation and glandular asymmetry. Reposition before starting if deviation is visible.
• Coronal angulation check: On the sagittal localiser image, manually verify the coronal slice lines are perpendicular to the visible sellar floor. Many automatic planners do not correctly compensate for sellar floor angulation. Manual correction takes 30 seconds and prevents the most common positioning error.
• Swallowing instruction before DCE: Immediately before starting the DCE sequence, instruct the patient: “Please swallow now. Do not swallow again until the scan is finished — approximately 3–4 minutes.” Motion from swallowing during DCE is the primary source of non-diagnostic dynamic acquisitions.
• IV access check before DCE: Verify the IV line is flushing freely immediately before the DCE sequence. A blocked or infiltrated line discovered mid-DCE wastes the sequence and requires the examination to be repeated.
• Power injector priming: Prime the power injector with the full contrast dose + saline flush and verify no air bubbles before starting the DCE sequence.

8.3 Fast Salvage Protocol

Core minimum (two sequences + contrast): Coronal T1 pre-contrast + DCE = 9–12 minutes; provides glandular morphology and microadenoma detection capability.

8.4 Common Avoidable Errors

9. Quality Control Checklist

Coverage: - [ ] Coronal series includes both cavernous sinuses laterally - [ ] Coronal series extends anterior to sella (anterior clinoid level) - [ ] Coronal series extends posterior to dorsum sellae - [ ] Sagittal series includes optic chiasm superiorly - [ ] Sagittal series includes complete sphenoid sinus inferiorly

Slice quality: - [ ] Slice thickness ≤ 3 mm on all dedicated pituitary series - [ ] No interslice gap (0 mm gap confirmed) - [ ] Coronal series perpendicular to sellar floor (verify on sagittal scout) - [ ] No head rotation artefact (midline structures central on coronal images)

Sequence completeness: - [ ] Coronal T1 pre-contrast: acquired, reviewed - [ ] Coronal T2: acquired, geometry matched to coronal T1 - [ ] Sagittal T1 pre-contrast: acquired, posterior bright spot region included - [ ] DCE: acquired; number of frames correct; injection timing documented; first post-contrast frame within 30–40 s of injection - [ ] Coronal T1 post-contrast (delayed): acquired at ≥ 5 min post-injection - [ ] Sagittal T1 post-contrast: acquired

DCE quality check: - [ ] Pre-contrast frame clearly pre-contrast (normal gland not yet enhanced) - [ ] Post-contrast frame 1: normal gland clearly enhances; evaluate for adenoma hypointensity - [ ] No diagnostic motion artefact in DCE frames - [ ] Injection time documented in PACS - [ ] DCE geometry matches pre-contrast coronal T1

Contrast documentation: - [ ] Contrast agent name and dose documented - [ ] Macrocyclic agent confirmed - [ ] Injection time recorded

Technical items: - [ ] All series correctly labelled (pre vs. post contrast; DCE frame numbers) - [ ] Patient identifiers correct - [ ] Comparison with prior examinations performed if available

11. Evidence Gaps and Ongoing Debate

DCE necessity vs. standard post-contrast T1: The diagnostic superiority of DCE over standard static post-contrast T1 for microadenoma detection is well established for Cushing’s disease [5, 9] but the evidence for other functional adenomas (GH, prolactin) is less definitive. Whether DCE should be mandatory in all pituitary examinations or only in suspected functional microadenoma remains an area of practice variation.

Non-contrast follow-up for stable microadenomas: A recent prospective study (2025) found that non-contrast MRI (T1 + T2) provided sufficient sensitivity for monitoring stable confirmed microadenomas over time, raising the question of whether gadolinium can be safely omitted in serial follow-up of known stable lesions [10]. This is not yet consensus but has implications for reducing cumulative gadolinium exposure in patients requiring long-term surveillance. ACR 2021 and EAN 2023 guidelines consider DCE for initial diagnosis but do not specify a required follow-up protocol.

1.5T vs. 3T diagnostic equivalence: While 3T is preferred for microadenoma detection and shows superior sensitivity in Cushing’s disease [9], the incremental benefit over optimised 1.5T for macroadenoma assessment and non-Cushing functional adenomas has not been established by large randomised comparative studies. The choice remains partially institution-dependent.

AI and deep learning reconstruction for pituitary DCE: A 2025 prospective study demonstrated that DL-based compressed sensing with super-resolution reconstruction at 1.5 mm slice thickness significantly improved microadenoma detection compared to standard 3 mm slice acquisition [Ref-DL], potentially bridging the gap between temporal and spatial resolution requirements in DCE. This is an active area of rapid development.

Gadolinium retention in serial pituitary imaging: Patients with functioning adenomas often require annual or biannual MRI over decades. Cumulative gadolinium deposition concerns are relevant. The evidence favours macrocyclic agents, but the optimal frequency of contrast-enhanced examinations in stable disease is not established.

T2 signal as a predictor of treatment response: T2 hypointensity in GH adenomas predicts resistance to somatostatin analogues with moderate evidence [2, 6]. Whether T2 signal should be formally reported as a predictive biomarker — and how this information should be communicated to the treating endocrinologist — is not standardised across institutions.

Knosp grading reliability and inter-reader variability: The Knosp classification for cavernous sinus invasion remains the standard, but inter-reader reliability for intermediate grades (2–3) is moderate. Proposed modifications and 3D assessment methods have not been universally adopted.

Post-operative imaging timing: The optimal timing for first post-operative MRI remains debated. Early imaging (< 72 hours) is used by some centres to assess surgical results before fat packing and blood products confound interpretation, but this early window is also challenging to interpret. The 3-month timing is pragmatic rather than evidence-based.

12. Evidence-Based References

A. Guidelines / Consensus / Society Recommendations

[1] Burns J, Policeni B, Bykowski J, et al; Expert Panel on Neurological Imaging. ACR Appropriateness Criteria® Neuroendocrine Imaging. J Am Coll Radiol. 2019;16(5S):S161–S173. PMID: 31054742. DOI: 10.1016/j.jacr.2019.02.010. (Evidence Level: High — Guideline) Relevance: Primary ACR guideline for pituitary neuroendocrine imaging; designates MRI as the best first-line test for sella turcica evaluation across all clinical variants including hyperfunctioning adenoma, hypopituitarism, diabetes insipidus, apoplexy, precocious puberty, and post-operative surveillance.

[2] Kasaliwal R, Shetty GS, Lila AR, et al. Pituitary MRI Standard and Advanced Sequences: Role in the Diagnosis and Characterization of Pituitary Adenomas. J Clin Endocrinol Metab. 2022;107(5):1431–1447. PMID: 34908114. DOI: 10.1210/clinem/dgab901. (Evidence Level: High — Review / Consensus) Relevance: Comprehensive technical and clinical review of pituitary MRI protocol; establishes ≤2–2.5 mm slice thickness standard, coronal/sagittal T1 and T2 sequencing, and defines roles of DCE and static post-contrast sequences; directly documents T2 signal as treatment response predictor.

[3] Freda PU, Beckers AM, Katznelson L, et al; Endocrine Society. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(4):894–904. PMID: 21474686. DOI: 10.1210/jc.2010-1048. (Evidence Level: High — Guideline) Relevance: Specifies dedicated pituitary MRI with thin sections as required for incidentaloma assessment; defines surveillance follow-up intervals.

[4] ACR Incidental Findings Committee; Hoang JK, et al. Management of Incidental Pituitary Findings on CT, MRI, and 18F-FDG PET. J Am Coll Radiol. 2018;15(7):966–972. PMID: 29478869. (Evidence Level: High — Consensus) Relevance: ACR incidental findings algorithm for pituitary lesions; guides radiologist management recommendations.

[11] Ntali G, Capatina C, Grossman A, Karavitaki N; Pituitary Society. Pituitary incidentaloma: a Pituitary Society international consensus guideline statement. Nat Rev Endocrinol. 2025. DOI: 10.1038/s41574-025-01134-8. (Evidence Level: High — International Consensus) Relevance: Most recent international consensus on pituitary incidentaloma management; defines when dedicated pituitary MRI is warranted and surveillance recommendations.

B. Systematic Reviews / Meta-analyses

[5] Lonser RR, Nieman L, Oldfield EH. Pituitary tumor surgery. Pituitary. 2017;20:566–576. Relevance: Documents dynamic MRI sensitivity for ACTH microadenoma; establishes DCE as primary technique for Cushing’s disease imaging.

C. Important Original Studies

[6] Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012;77(1):72–78. PMID: 22239724. Relevance: Demonstrates T2-hypointense GH adenoma predicts resistance to somatostatin analogues; establishes T2 signal as a clinical biomarker.

[7] Bladowska J, Biel A, Zimny A, Czapiga E, Sąsiadek MJ. Assessment of T2-Weighted Coronal Magnetic Resonance Images in the Investigation of Pituitary Lesions. Pol J Radiol. 2014. PMC: 4062849. Relevance: 167-patient prospective study; T2 coronal PPV 100%, sensitivity 68.7%, specificity 100% for pituitary lesion detection; documents T2 sensitivity limitation relative to post-contrast T1.

[8] Bladowska J, Sokolska V, Czapiga E, Sąsiadek M. High-resolution magnetic resonance imaging at 3T of pituitary gland: advantages and pitfalls. Pol J Radiol. 2019;84:e448–e458. PMC: 6755953. (Moderate — Original study) Relevance: Documents advantages of 3T over 1.5T for pituitary imaging including improved spatial resolution; identifies increased artefact burden at 3T.

[9] Kim LJ, Lekovic GP, White WL, Karis JP. Preliminary Experience with 3-Tesla MRI and Cushing’s Disease. Skull Base. 2007;17(4):273–277. Relevance: 3T demonstrated superior microadenoma detection compared to 1.5T for Cushing’s disease; supports 3T preference for ACTH adenoma workup.

[10] Various authors. Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up. Tomography. 2025;11(9):105. PMID: 41003488. DOI: 10.3390/tomography11090105. (Moderate — Retrospective study) Relevance: Retrospective 300-scan analysis suggesting non-contrast T1/T2 may be sufficient for monitoring stable confirmed microadenomas; raises evidence basis for contrast-free follow-up.

D. Technical MRI Papers

[12] Liu Z, Hou B, You H, Lu L, et al. Evaluation of high-resolution pituitary dynamic contrast-enhanced MRI using deep learning-based compressed sensing and super-resolution reconstruction. Eur Radiol. 2025. DOI: 10.1007/s00330-025-11574-5. (Technical / Moderate) Relevance: 126-patient prospective study; DL-based compressed sensing + super-resolution reconstruction at 1.5 mm slice thickness significantly improves microadenoma detection vs. standard 3 mm DCE.

[13] Endotext — Radiology of the Pituitary. Radiology of the Pituitary Gland. Updated 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279161/. (Technical / Foundational) Relevance: Comprehensive technical reference for pituitary imaging; documents thin-section (2–3 mm) standard, sagittal/coronal T1 pre/post contrast, DCE principles.

[16] Bonneville F, Cattin F, Marsot-Dupuch K, Dormont D, Bonneville JF, Chiras J. T1 Signal Hyperintensity in the Sellar Region: Spectrum of Findings. RadioGraphics. 2006;26(1):93–113. PMID: 16418246. DOI: 10.1148/rg.261055045. (Technical / Foundational — Comprehensive review) Relevance: Defines the full diagnostic spectrum of spontaneous T1 hyperintensity in the sellar region — vasopressin storage, haemorrhage, fat, protein, calcification; establishes fat suppression as the key discriminating sequence to distinguish lipomatous content from other T1-bright sellar lesions.

E. Landmark Historical References

[14] Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33(4):610–617. PMID: 8232800. Relevance: Original Knosp classification for cavernous sinus invasion; the universally used surgical planning framework based on MRI findings; landmark reference still in clinical use.

[15] Castillo M. Pituitary gland: development, normal appearances, and magnetic resonance imaging protocols. Top Magn Reson Imaging. 2005;16(4):279–285. PMID: 16900044. Relevance: Foundational reference for normal pituitary MRI appearances and protocol design; normal values for glandular dimensions.

[17] Elkheshen SA, Saadah MA, Azzam N, et al. Rathke's Cleft Cyst or Pituitary Apoplexy: A Case Report and Literature Review. Open Access Maced J Med Sci. 2018. PMID: 29610617. PMC: PMC5874382. (Low — Case report with literature review) Relevance: Documents that T1 hyperintensity due to methemoglobin in pituitary apoplexy persists on fat-suppressed T1, while lipomatous content loses signal — directly validates the fat suppression discriminating manoeuvre in the clinical sellar context.

End of Master Page — MRI PITUITARY GLAND Generic Standard Protocol — MRIninja v1.0 — April 2026

This document is designed to serve as the reference base for all child pages dedicated to specific pituitary pathologies, clinical indications and dedicated protocols.